We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TAMPA, FL -- (Marketwire) -- 04/23/09 -- Nanobac Pharmaceuticals (PINKSHEETS: NNBP) merger partner Eureka Genomics, a leader in analysis of next generation genomic sequencing data and Glycos...
TAMPA, FL -- (Marketwire) -- 04/21/09 -- Nanobac Pharmaceuticals, Inc. (PINKSHEETS: NNBP) and its privately held merger partner Eureka Genomics, which applies its proprietary functional genomics...
TAMPA, FL and HERCULES, CA -- (Marketwire) -- 04/13/09 -- Nanobac Pharmaceuticals, Inc. (PINKSHEETS: NNBP) and privately held Eureka Genomics announced the signing of a definitive merger...
TAMPA, FL and HERCULES, CA -- (Marketwire) -- 03/17/09 -- Nanobac Pharmaceuticals Inc. (PINKSHEETS: NNBP) (Nanobac) and privately held Eureka Genomics (EG) announced the signing of a Memorandum...
TAMPA, FL -- (Marketwire) -- 02/27/09 -- Nanobac Pharmaceuticals Inc. (PINKSHEETS: NNBP) ("Nanobac" or "the Company") announced that it is actively pursuing strategic alliances and potential...
TAMPA, FL ("Nanobac" or "the Company") announces the multicenter publication of independent research, which reports on the characterization of calcifying nanoparticles (CNPs), formerly known as...
TAMPA, FL ("Nanobac" or "the Company") announces an audio interview of scientists at Mayo Clinic that discusses calcifying nanoparticles (CNPs or NPs) in arterial and kidney stone disease. The...
TAMPA, FL ("Nanobac" or "the Company") is pleased to announce the signing of a research collaboration agreement with BioChemics Inc. (BCI) to utilize BCI's leading patented drug delivery...
TAMPA, FL ("Nanobac" or "the Company") announces publication in the International Journal of Nanomedicine research that scientists from the University of California San Francisco collaborating...
TAMPA, FL ("Nanobac" or "the Company") announces publication in the International Journal of Nanomedicine research that scientists from the University of California San Francisco collaborating...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 2000 | 1.0E-6 | CS |
26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 714 | 1.0E-6 | CS |
52 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 65310 | 1.0E-6 | CS |
156 | -9.9E-5 | -99 | 0.0001 | 0.0001 | 1.0E-6 | 90449 | 2.74E-6 | CS |
260 | -0.000199 | -99.5 | 0.0002 | 0.0076 | 1.0E-6 | 312234 | 0.00103374 | CS |
Symbol | Price | Vol. |
---|---|---|
AITXArtificial Intelligence Technology Solutions Inc (PK) | US$ 0.00275 (0.00%) | 51.06M |
GTEHGenTech Holdings Inc (CE) | US$ 0.000001 (0.00%) | 48.25M |
HMBLHUMBL Inc (PK) | US$ 0.0002 (-33.33%) | 42.65M |
CBGLCannabis Global Inc (PK) | US$ 0.00015 (50.00%) | 41.81M |
GTVHGolden Triangle Ventures Inc (PK) | US$ 0.0008 (33.33%) | 41.61M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions